Medicare Access and CHIP Reauthorization Act

What Is the Medicare Access and CHIP Reauthorization Act?

The Medicare Access and CHIP Reauthorization Act, often called MACRA, is a 2015 federal law that changed how Medicare pays many clinicians. It repealed the old sustainable growth rate formula for physician payments and created the Quality Payment Program, which ties parts of Medicare clinician payment to quality, cost, improvement activities, and participation in advanced payment models.

MACRA is not a Medicare enrollment option for beneficiaries. It is a payment and quality framework that affects physicians, clinicians, medical groups, and the Medicare system that pays them.

What MACRA Changed

Before MACRA, Medicare physician payment policy was tied to the sustainable growth rate formula. That formula regularly produced scheduled payment cuts that Congress often delayed or overrode. MACRA replaced that unstable framework with a new payment structure.

The law also extended and reauthorized funding connected to the Children's Health Insurance Program, which is the CHIP portion of the name. In everyday Medicare finance discussions, however, MACRA is usually discussed because of clinician payment reform and the Quality Payment Program.

Quality Payment Program Paths

Payment and Practice Effects

MACRA matters because it links Medicare reimbursement to measured performance rather than only volume of services. For medical practices, that can affect revenue forecasting, reporting costs, technology investment, staffing, and participation in value-based payment models.

For hospitals, physician groups, and health systems, MACRA can influence acquisition strategy, network design, quality infrastructure, and how much risk an organization is willing to accept. Smaller practices may face different pressures than large systems because reporting and compliance infrastructure can be costly.

Effect on Medicare Beneficiaries

Medicare beneficiaries usually do not experience MACRA as a separate benefit or card. Its effects are more indirect. Payment incentives can influence how clinicians document care, coordinate treatment, invest in quality measurement, and participate in Medicare payment models.

That does not mean the law is irrelevant to patients. When payment systems change, provider participation, practice consolidation, care management, and access can be affected over time. The link is indirect, but the financial incentives are real.

MACRA Versus Medicare Advantage

MACRA is sometimes confused with Medicare Advantage because both involve payment models and quality measurement. Medicare Advantage is a private-plan alternative to Original Medicare for beneficiaries. MACRA is a federal law that changed parts of clinician payment within Medicare.

A beneficiary can choose Original Medicare or Medicare Advantage without directly choosing MACRA. Clinicians and organizations, not ordinary beneficiaries, are the primary operational audience for MACRA's payment rules.

Where It Can Mislead

MACRA is often described as value-based care, but the phrase can be too broad. The actual effect depends on program year, clinician type, reporting requirements, performance scores, model participation, and CMS rulemaking. The law created the framework; the details are administered through evolving Medicare payment rules.

It is also easy to overstate the immediate patient-level effect. A Medicare patient may never hear the acronym during a doctor visit, even though the practice may be managing MACRA-related reporting behind the scenes.

The Bottom Line

The Medicare Access and CHIP Reauthorization Act is a major Medicare payment law. Its practical importance is that it replaced an unstable physician-payment formula and created a framework that ties clinician reimbursement more closely to quality reporting and alternative payment models.